GERN
GERON CORP
Key Financials
Operating Income
$-68585000
↑ 60.5%
Revenue
$237000
↓ 60.2%
Net Income
$-83500000
↑ 52.2%
Total Assets
$570.5M
↓ 3.9%
EPS (Diluted)
$-0.13
↑ 51.9%
Shareholders' Equity
$225.9M
↓ 19.4%
Total Liabilities
$344.7M
↑ 10.0%
Cash & Equivalents
$77.6M
↓ 1.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/8/2026 | View on SEC |
| 10-Q | 5/6/2026 | View on SEC |
| 4 | 4/14/2026 | View on SEC |
| 3 | 4/14/2026 | View on SEC |
| ARS | 4/7/2026 | View on SEC |
| DEFA14A | 4/7/2026 | View on SEC |
| DEF 14A | 4/7/2026 | View on SEC |
| 4 | 4/1/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GERN |
| Company Name | GERON CORP |
| CIK | 886744 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 6504737700 |